The DSO De Novo Boom: Why Dental Groups Are Building Instead of Buying
Several DSOs are diversifying beyond acquisitions by ramping up de novo practice development, a shift driven by tighter deal supply, valuation pressure, and the operational appeal of building from scratch. Smile Partners launched its first de novo as a deliberate break from its acquisition-only model, while Park Dental Partners is directing post-IPO capital toward new office openings in existing markets. The appeal is practical: de novos offer DSOs full control over patient experience, staffing culture, and brand consistency from day one, without integration costs of acquired practices. At a moment when acquisition targets are harder to find and multiples remain elevated, de novo development is emerging as a high-conviction growth strategy for platforms with strong operational infrastructure.
For PE-backed dental platforms weighing capital deployment, this piece captures the de novo shift in concrete terms — naming specific DSOs making the pivot. Operators should assess their own organic development capacity now, before competitive density in key markets makes de novo economics harder to justify.
While we aim to share useful and relevant resources, we do not guarantee the accuracy of content on this site or any external links. Views and opinions expressed in referenced content do not necessarily reflect those of Healthcare Growth Strategies.